Ibrolipim increases ABCA1/G1 expression by the LXRα signaling pathway in THP-1 macrophage-derived foam cells

Si-guo CHEN1, 3, #, Ji XIAO1, 2, #, Xie-hong LIU1, Mei-mei LIU1, Zhong-cheng MO1, Kai YIN1, Guo-jun ZHAO1, Jin JIANG1, Li-bao CUI1, Chun-zhi TAN1, Wei-dong YIN1, Chao-ke TANG1, *

1Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province, Life Science Research Center, University of South China, Hengyang 421001, China; 2Department of Anesthesiology, the Second Affiliated Hospital of University of South China, Hengyang 421001, China; 3Department of Physiology, Xiangnan University, Chenzhou 423000, China

Aim: To determine the effects and potential mechanisms of ibrolipim on ATP-binding membrane cassette transporter A-1 (ABCA1) and ATP-binding membrane cassette transporter G-1 (ABCG1) expression from human macrophage foam cells, which may play a critical role in atherogenesis.

Methods: Human THP-1 cells pre-incubated with ox-LDL served as foam cell models. Specific mRNA was quantified using real-time RT-PCR and protein expression using Western blotting. Cellular cholesterol handling was studied using cholesterol efflux experiments and high performance liquid chromatography assays.

Results: Ibrolipim 5 and 50 μmol/L significantly increased cholesterol efflux from THP-1 macrophage-derived foam cells to apoA-I or HDL. Moreover, it upregulated the expression of ABCA1 and ABCG1. In addition, LXRα was also upregulated by the ibrolipim treatment. In addition, LXRα small interfering RNA completely abolished the promotion effect that was induced by ibrolipim.

Conclusion: Ibrolipim increased ABCA1 and ABCG1 expression and promoted cholesterol efflux, which was mediated by the LXRα signaling pathway.

Keywords: ATP-binding membrane cassette transporter A-1; ATP-binding membrane cassette transporter G-1; ibrolipim; liver X receptor α; atherosclerosis; RNA interference; high density lipoprotein; apolipoprotein; cholesterol

Original Article

Introduction

Coronary artery disease (CAD) is a major cause of mortality in advanced societies[1, 2]. Multiple factors contribute to the formation of lesions that ultimately lead to CAD. A major event in the progression of atherosclerosis is the differentiation of monocytes to macrophages that accumulate lipoprotein-derived cholesterol to form foam cells within the arterial wall[3]. Excess unesterified cholesterol (UC) is toxic to cells; therefore, cells have developed several ways to protect themselves against cholesterol toxicity. One key pathway is the efflux of cholesterol to extracellular “acceptors” via cholesterol exporters like ATP-binding membrane cassette transporter A-1 (ABCA1) and ATP-binding membrane cassette transporter G-1 (ABCG1)[4, 5].

Ibrolipim is an effective lipoprotein lipase (LPL) activator[6]. It has previously been reported that ibrolipim increases lipoprotein lipase (LPL) mRNA in tissues and LPL activity in post-heparin plasma, resulting in a reduction in plasma triglyceride levels and an elevation of HDL. Previous studies from our laboratory and others have also shown that increasing LPL activity in skeletal muscle results in decreased fat accumulation, and long-term administration of ibrolipim protects against the development of experimental atherosclerosis in animals[6-8]. However, the detailed mechanism for cholesterol transport proteins induced by ibrolipim is unclear.

Recently, our laboratory revealed that the liver X receptors (LXR) synthetic agonist T0901317 promoted ABCA1 gene and protein levels in the aorta, liver, and small intestine of apoE-/- mice and significantly increased cholesterol efflux from peritoneal macrophages[9]. We also showed that IFN-γ may first downregulate the expression of LXRα through the
JAK/STAT1 signaling pathway and then decrease expression of ABCA1 and cholesterol efflux in THP-1 macrophage-derived foam cells\textsuperscript{[19]}. In addition, eicosapentaenoic acid (EPA) reduces ABCA1 serine phosphorylation and impairs ABCA1-dependent cholesterol efflux through a cAMP/PKA pathway in THP-1 macrophage-derived foam cells\textsuperscript{[21]}. The objective of this study was to investigate the effects of ibrolipim on the key exporters of macrophage cholesterol efflux ABCA1 and ABCG1, on the nuclear transcription factor LXRα that regulates their expression, and on macrophage cholesterol handling.

**Materials and methods**

**Materials**

Ibrolipim ([(4-(4-bromo-2-cyano-phenylcarbamoyl)-benzyl]-phosphonic acid diethyl ester; Chemical Abstracts Service (CAS) 133208-93-2; lot Ng C00C99) that was synthesized in the New Drug Research Laboratory of Otsuka Pharmaceutical Factory (Tokushima, Japan) was provided by Prof Wei-dong Yin. HDL and lipid-free apoA-I were obtained from Calbiochem (Cambridge, MA). Rabbit polyclonal anti-ABCA1, anti-ABCG1, anti-LXRα, and anti-β-actin antibody were obtained from Abcam (Cambridge, UK). CellTiter 96AQ aqueous One Solution Reagent was from Promega (Madison, WI). pSilencer2.1-U6-Hygro was obtained from Ambion Company. Lipofectamine\textsuperscript{TM} 2000 was from the Invitrogen Company. 3-[4,5-Dimethylthiazol-2-yl]-2,5-tetrazolium bromide (MTT) and other chemicals of reagent grade were obtained from Sigma (St. Louis, MO).

**Cell culture**

Human THP-1 cells were cultured in RPMI-1640 supplemented with 0.1% nonessential amino acids, penicillin (100 U/mL), streptomycin (100 μg/mL), and 20% fetal bovine serum (FBS) at 37 °C in 5% CO\textsubscript{2} at a cell density of 0.2 to 1.0×10\textsuperscript{6}/mL. After three to four days, cells were treated with PMA (160 nmol/L) for 24 h, and the medium was then replaced by a serum-free medium containing oxLDL (50 μg/mL) for 48 h in order for the cells to become fully differentiated macrophages before their use in experiments.

**Cell proliferation and cytotoxicity assay**

A cell cytotoxicity assay was assessed by measuring the activity of mitochondrial dehydrogenase as described previously\textsuperscript{[12]}. THP-1 cells were plated in 96-well plates with a density of 1×10\textsuperscript{4}/well. The medium was replaced after 24 h. The cells were cultured as indicated above. After treatment with ibrolipim at different concentrations for 24 h, 10 μL/well of CellTiter 96AQ aqueous One Solution Reagent [3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium bromide (MTT) reagent] was added. After incubation at 37 °C for 1 h in a humidified 5% CO\textsubscript{2} atmosphere, the absorbance at 490 nm was recorded with an ELISA plate reader. “Control” refers to incubations in the presence of vehicle only (0.1% of DMSO or ethanol) and was considered to have 100% viable cells.

**Transfection for LXRα silencing**

Short-interfering RNA (siRNA) specific for human LXRα (Santa Cruz Biotechnology) and nonsilencing control siRNA were synthesized by the Biology Engineering Corporation in Shanghai, China. The double-stranded DNA for siRNA was ligated with a linearized pSilencer 2.1-U6 siRNA expression vector at BamHI and HindIII sites. The products were transformed into competent *Escherichia coli* DH5α cells and cultured on Luria-Bertani (LB) plates with 100 μg/mL ampicillin. Ampicillin-resistant colonies were selected by restriction digestion and confirmed by DNA sequencing. For transfection with small interfering RNA (siRNA), foam cells were plated in 96-well plates at a density 2×10\textsuperscript{4} cells per well. The next day, cells were transfected with LXRα siRNA in OPTI-MEM with 5 μg/mL Lipofectamine 2000 (Invitrogen). The final siRNA concentration was 100 nmol/L. The efficiency of transfection was approximately 50% as assessed with a fluorescein-labeled RNA probe. After 48 h of transfection, ibrolipim (50 μmol/L) was added to the culture medium. The cells were cultured for an additional 24 h before expression or functional studies were performed. The target sequence for human LXRα siRNA was AAGTACACAGGAGCCCATCTT, and the target sequence for control non-silencing siRNA was AATTCTCCGAACGT-GTACGCT. In comparison to the control siRNA, the siRNA of LXRα suppressed the expression of LXRα proteins by 84% according to Western blot analysis.

**Western blot analyses**

Cellular and whole-tissue proteins were extracted. An equal amount of total proteins (40 μg) was loaded onto a 10% SDS-polyacrylamide electrophoresis gel and was electrophoresed for 2 h at 100 V in buffer containing 25 mmol/L Tris base, 250 mmol/L glycine and 0.1% SDS. After electrophoresis, the proteins were electrically transferred to an immobilon-P transfer membrane in buffer containing 25 mmol/L Tris, 192 mmol/L glycine, 20% methanol, and 0.005% SDS. After transfer, the membrane was blocked in TBST (20 mmol/L Tris base, pH 7.6, 150 mmol/L NaCl, and 0.1% Tween-20) containing 5% skim milk for 4 h at room temperature. The membrane was incubated with antibodies against ABCA1, ABCG1, LXRα, and β-actin in the blocking solution at 4°C overnight. The membrane was then washed three times with TBST for 30 min, incubated with secondary antibody in the blocking solution for 50 min at room temperature, and washed three times with TBST for 30 min. Immunoreactivity was detected by the ECL test. The protein content was calculated by densitometry using Labwords analysis software.

**RNA isolation and real-time quantitative PCR analysis**

Total RNA from cells was extracted using TRIzol reagent in accordance with the manufacturer’s instructions. Real-time quantitative PCR, using SYBR Green detection chemistry, was performed on a Roche light Cycler Run 5.32 Real-Time PCR System. A master mixture for each quadruple was set up in a total reaction volume of 30 μL with 5 μL cDNA (in a 1:5 dilution), 15 μL 2×TaqMan Universal Master Mix, No AmpErase...
UNG (Applied Biosystems), 5 μL of diethylpyrocarbonate-treated water (Ambion Ltd., Huntingdon, UK), and 1.5 μL 20× primer/probe set (Assay-on-Demand Assay Mix; Applied Biosystems). From this mixture, an aliquot of 5 μL was placed in each of the four wells. The thermal cycling conditions were 95 °C for 10 min, then 40 cycles of 95 °C for 15 s and 60 °C for 1 min. Quantitative measurements were determined using the ΔΔCₚ method and expression of β-actin was used as the internal control. The sequences of the primers are as shown in Table 1.

**Cellular cholesterol efflux experiments**
Cells were cultured as indicated above. Then they were labeled with 0.2 μCi/mL [3H]cholesterol. After 72 h, cells were subsequently washed with phosphate-buffered saline (PBS) and incubated overnight in RPMI 1640 medium containing 0.1% (v/v) bovine serum albumin (BSA) to allow equilibration of the [3H]cholesterol in all of the cellular pools. Equilibrated [3H]cholesterol-labeled cells were washed with PBS and incubated in 2 mL of efflux medium containing RPMI 1640 medium and 0.1% BSA with or without apoA-I (50 μg/mL) or HDL (μg/mL). An 150 μL sample of efflux medium was obtained at the designated times and passed through a 0.45-μm filter to remove any floating cells. The monolayers were washed twice in PBS, and cellular lipids were extracted with isopropanol. Medium and cell-associated [3H]cholesterol was then measured by liquid scintillation counting. The percentage of efflux was calculated by the following equation: [total media counts/(total cellular counts+total media counts)]×100%.

**High performance liquid chromatography assays (HPLC)**
HPLC analysis was conducted as described previously.[13] Briefly, cells were washed with PBS three times. The appropriate volume (usually 1 mL) of 0.5% NaCl was added about 50–200 μg cellular proteins per mL. Cells were sonicated using an ultrasonic processor for 2 min. The protein concentration in the cell solution was measured using a BCA kit. A 50–200 μg of protein was used to measure the free cholesterol, and another aliquot was used for total cholesterol detection. Free cholesterol was then measured by liquid scintillation counting. The total reaction solution in each tube was incubated at 37 °C for 30 min, and 100 μL methanol:ethanol (1:1) was added to stop the reaction. Each solution was kept cold for 30 min to allow protein precipitation and then centrifuged at 1500 r/min for 10 min at 15 °C. Ten microliters of supernatant was applied onto a System Chromatographer (PerkinElmer Inc) that included a PerkinElmer series 200 vacuum degasser, a pump, a PerkinElmer series 600 LINK, and a PerkinElmer series 200 UV/vis detector, and a Discovery C-18 HLPC column (Supelco Inc). The column was eluted using isopropanol:n-heptane:acetonitrile (35:13:52) at a flow rate of 1 mL/min for 8 min. The absorbance at 216 nm was monitored, and the data were analyzed by Total Chrom software from PerkinElmer.

**Statistical analysis**
Data are expressed as means±SD. Results were analyzed by one-way ANOVA and Student’s t test using SPSS 13.0 software. P values of less than 0.05 were considered statistically significant.

**Results**
Upregulation of ABCA1 and ABCG1 expression by ibrolipim in THP-1 macrophage-derived foam cells
To investigate whether ibrolipim treatment can cause cell toxicity, the effects of different concentrations of ibrolipim on foam cell viability were compared using MTT reagent. As shown in Figure 1A, the difference in cell viability between different treatments was not statistically significant. These results indicate that the experimental concentrations of ibrolipim did not induce cell proliferation and cell death.

ABCA1 and ABCG1 are key players in reverse cholesterol transport and are critical in regulating cellular cholesterol homeostasis[14, 15]. To cast light on ibrolipim’s effect on ABCA1 and ABCG1, we investigated the expression levels of mRNA and protein for ABCA1 and ABCG1 in THP-1 macrophage-derived foam cells. As shown, ibrolipim increased ABCA1 and ABCG1 expression at both the transcriptional (Figure 1B and 1C) and translational levels (Figure 1D and 1E) in a dose-dependent and time-dependent manner. Used as a positive control, the LXR ligand T0901317 (5 μmol/L) increased

**Table 1.** Primer sequences for real-time quantitative PCR.

| Gene | GenBank No | Forward primer | Reverse primer |
|------|------------|----------------|---------------|
| ABCA1 | NM_005502 | 5'-GTCTCCTTCCCCGATTATCTGG-3' | 5'-AGTTCCCTGGAGGTCTTGTCAC-3' |
| ABCG1 | NM_004915 | 5'-CGGAGCCCCAAGTGGCTTG-3' | 5'-TTTCCAGATGTCATCCAGAAGATGC-3' |
| LXRα | NM_013839 | 5'-AGGCTCCATCCAGAAGCAGT-3' | 5'-GGGGACAAGAACAGTGCATGG-3' |
| β-actin | BC013835 | 5'-CTGGAACGGTGAAGGTCACA-3' | 5'-AACGGACTCTTGGTACAATGCA-3' |
ABCA1 and ABCG1 expression at 24 h.

Ibrolipim promotes cholesterol efflux in THP-1 macrophage-derived foam cells

Because ABCA1 and ABCG1 were upregulated by ibrolipim, we next determined the effect of ibrolipim on cholesterol efflux from THP-1 macrophage-derived foam cells by measuring $^3$H-cholesterol and cholesterol content. Significant increases of cholesterol efflux to apoA-I were observed in a concentration-dependent manner in response to ibrolipim treatment (Figure 1F). Next, a time course study was performed, and the differences in cholesterol efflux from foam cells to apoA-I between apoA-I only and ibrolipim-treated groups peaked at 12 and 24 h (Figure 1G). In addition, high performance liquid chromatography was used to measure cellular cholesterol content. The cellular cholesterol content was decreased while cholesterol efflux was increased by ibrolipim (Table 2), suggesting

Table 2. Cholesterol content in THP-1 macrophage-derived foam cells in response to Ibrolipim and apoA-I. The results are expressed as mean±SD from three independent experiments, each performed in triplicate. $^b$P<0.05 vs control group.

| Treatment          | 0 μmol/L | 0.5 μmol/L | 5 μmol/L | 50 μmol/L | T0901317 (5 μmol/L) |
|--------------------|----------|------------|----------|-----------|---------------------|
| TC                 | 437±42   | 415±35     | 312±24$^b$ | 274±26$^b$ | 252±21$^b$          |
| FC                 | 174±21   | 166±16     | 126±18$^b$ | 117±14$^b$ | 105±13$^b$          |
| CE                 | 263±22   | 249±21     | 186±13$^b$ | 157±18$^b$ | 147±16$^b$          |
| CE/TC (%)          | 60.1     | 60.0       | 59.6      | 57.2       | 58.3                |

THP-1 macrophage-derived foam cells were divided into five groups and cultured in medium with apoA-I (50 μg/mL) at 37 °C containing 0, 0.5, 5, and 50 μmol/L Ibrolipim or 5 μmol/L T0901317 for 24 h respectively. Cellular cholesterol and cholesterol ester were extracted as described above. HPLC was performed to determine the cellular total cholesterol (TC), free cholesterol (FC) and cholesterol ester (CE).
that ABCA1 expression can be upregulated by ibrolipim in foam cells. HDL, another acceptor of cholesterol and phospholipids transported by ABCG1, was also used to evaluate the effect of ibrolipim on cholesterol efflux in foam cells. Consistent with apoA-I, ibrolipim treatment also induced a significant increase of cholesterol efflux from foam cells to HDL in a dose- and time-dependent manner (Figure 1H and 1I). For directly measuring the cellular cholesterol content, ibrolipim-treated foam cells also showed a decrease compared with the control (HDL only, Table 3). Used as a positive control, the LXR ligand T0901317 (5 μmol/L) significantly increased cholesterol efflux from THP-1 macrophage-derived foam cells to apoA-I or HDL at 24 h.

**LXRα is involved in the upregulation of ABCA1 and ABCG1 induced by ibrolipim in THP-1 macrophage-derived foam cells**

The LXRs have been shown to regulate the expression of ABCA1 and ABCG1\[16, 17\], which serve as free-cholesterol and phospholipid translocators enabling cholesterol efflux from the macrophage to various acceptors, including nascent cholesterol-poor HDL, and thus have a central role in the regulation of reverse cholesterol transport. To further confirm whether LXRα expression can be affected by ibrolipim, real-

---

**Table 3.** Cholesterol content in THP-1 macrophage-derived foam cells in response to Ibrolipim and HDL. The results are expressed as mean±SD from three independent experiments, each performed in triplicate. *P<0.05 vs control group.

| Ibrolipim     | 0 μmol/L | 0.5 μmol/L | 5 μmol/L | 50 μmol/L | T0901317 (5 μmol/L) |
|---------------|----------|------------|----------|-----------|---------------------|
| TC            | 405±35   | 386±38     | 281±27\* | 242±23\*  | 221±20\*            |
| FC            | 161±24   | 154±19     | 116±21\* | 98±10\*   | 95±11\*             |
| CE            | 244±18   | 232±26     | 165±11\* | 144±17\*  | 26±13\*             |
| CE/TC (%)     | 60.3     | 60.1       | 58.7     | 59.4      | 57.2                |

THP-1 macrophage-derived foam cells were divided into five groups and cultured in medium with apoA-I (50 μg/mL) at 37 °C containing 0, 0.5, 5, and 50 μmol/L ibrolipim or 5 μmol/L T0901317 for 24 h, respectively. Cellular cholesterol and cholesterol ester were extracted as described above. And HPLC was performed to determine the cellular total cholesterol (TC), free cholesterol (FC) and cholesterol ester (CE).
time quantitative PCR and Western immunoblotting analyses were performed. As shown (Figure 2A–2D), the expression of LXRα mRNA and protein was increased in a dose-dependent and time-dependent manner when cells were treated with ibrolipim. We then examined the effect of LXRα siRNA on the upregulation of ABCA1 and ABCG1, which was induced by ibrolipim. Treatment with siRNA for LXRα down-regulated LXRα protein expression by 88% (Figure 2E) and completely abolished the upregulation of ABCA1 and ABCG1 expression by ibrolipim (Figure 2F and 2G). At the same time, cellular cholesterol efflux to apoA-I (Figure 2H) or HDL (Figure 2I) in cells treated by the combination of LXRα siRNA and ibrolipim was completely reversed when compared with cells treated by ibrolipim alone.

Discussion
Atherosclerosis is a chronic pathological process, and it can take decades for severe atheromatous lesions to develop in humans[30]. Macrophages play a central role in the formation of arterial lesions by accumulating excessive amounts of lipids, mainly cholesterol ester (CE), through the uptake of modified lipoproteins. This occurs by a variety of mechanisms, including the scavenger receptor pathways such as scavenger receptors A (SR-A) and CD36[19]. During this process, cholesterol efflux may play a pivotal role in the removal of excess cholesterol from extra hepatic cells including macrophages and vascular smooth muscle cells (VSMCs)[20]. Thus, decreased cholesterol efflux from the arterial wall may potentially promote the progression of atherosclerosis. The principal molecules involved in the efflux of cholesterol from macrophage foam cells are ABCA1 and ABCG1[14, 15]. ABCA1, the mutant molecule in Tangier disease, is involved in the efflux of cholesterol from peripheral tissue macrophages to lipid-free apolipoproteins, and in particular to apoAl[20–22], whereas ABCG1 facilitates cellular cholesterol efflux from macrophages to lipided particles such as mature HDL, but not to lipid-free apolipoproteins[23, 24].

It has previously been reported that ibrolipim increased LPL mRNA levels, LPL protein mass, and LPL activity in post-heparin plasma and reduced plasma TG levels with concomitant increases of HDL-C levels in animals with lipid disorder. Kusunoki et al have reported that ibrolipim treatment suppresses fat accumulation in a high-fat diet-fed rat model. Tsutsumi et al have demonstrated that increasing LPL activity results in the elevation of high-density lipoprotein cholesterol and that long-term administration of ibrolipim protects against the development of atherosclerosis in rats fed with an atherogenic diet[6–8]. Recently, our laboratory revealed that ibrolipim upregulates the expression of NPC1 by the LXRα pathway in THP-1 macrophage-derived foam cells[25]. Moreover, we also showed that ibrolipim upregulated ABCA1 and inhibited diet-induced atherosclerosis in Chinese Bama minipigs[8]. To further investigate the detailed mechanism for cholesterol transport proteins induced by ibrolipim, we first demonstrated that ibrolipim could upregulate the expression of ABCA1 and ABCG1 as well as promote cholesterol efflux in THP-1 macrophage-derived foam cells.

Expression of both ABCA1 and ABCG1 may be suppressed by the zinc finger protein 202 (ZNF202) and upregulated by cholesterol loading or by treatment with specific oxysterols including 25-, 20(S)-, and 22(R)-hydroxycholesterol[16, 17, 26]. It is clear that induction of both ABCA1 and ABCG1 by these specific oxysterols depended on activation of LXRα[16, 17, 26]. To further understand the role of LXRα in the upregulation of ABCA1 and ABCG1 expression by ibrolipim, we investigated the effect of ibrolipim on the expression of LXRα to find out whether the expression of LXRα is changed during the course of treatment. It turned out that LXRα expression was also increased by ibrolipim in THP-1 macrophage-derived foam cells. LXRα siRNA was then used to see whether LXRαs is involved in the upregulation of ABCA1 and ABCG1 induced by ibrolipim. LXRα siRNA completely abolished the upregulation of ABCA1 and ABCG1 expression by ibrolipim. Cellular cholesterol efflux promoted by ibrolipim was also reversed by LXRα siRNA. Therefore, we speculate that LXRα was involved in the upregulation of ABCA1 and ABCG1 induced by ibrolipim in THP-1 macrophage-derived foam cells.

In summary, the results of our study indicate that ibrolipim upregulates ABCA1 and ABCG1 expression as well as cholesterol efflux in THP-1 macrophage-derived foam cells. Expression of LXRα is also increased by ibrolipim treatment. However, enhanced ABCA1 and ABCG1 expression that was induced by ibrolipim was completely abolished by LXRα small interfering RNA. All of these findings suggest that ibrolipim may first upregulate the expression of LXRαs and then increase the expression of ABCA1 and ABCG1 as well as cholesterol efflux in THP-1 macrophage-derived foam cells. These observations may provide new insights into the treatment of atherosclerosis.

Acknowledgements
The authors gratefully acknowledge the financial support from the National Natural Sciences Foundation of China (81070220), Post-doctor Sciences Foundation of China (2005037157) and Heng Yang Joint Funds of the Hunan Provincial Natural Sciences Foundation of China (10jj9019), and the National Major Basic Research Program of China (973 Program) (grant No. 2006CB503808).

Author contribution
Si-guo CHEN, Ji XIAO, and Chao-ke TANG designed the research; Si-guo CHEN, Ji XIAO, Jin JIANG, Li-bao CUI, and Mei-mei LIU performed the research; Wei-dong YIN, Guo-jun ZHAO, and Chao-ke TANG designed the research; Si-guo CHEN, Ji XIAO, and Chao-ke TANG contributed new analytical reagents and tools; Xie-hong LIU, Zhong-cheng MO, Kai YIN, and Chun-zhi TAN analyzed data; Ji XIAO wrote the paper.

Abbreviations
ABCA1: ATP-binding cassette transporter A1; ABCG1: ATP-binding cassette transporter G1; As: atherosclerosis; CAD: Coronary artery disease; LXRα: liver X receptors; RXR: retinoid X receptor; ox-LDL: oxidized low density lipoprotein; PMA: phorbol 12-myristate 13-acetate; TC: total cholesterol; CE:
cholesterol ester; FC: free cholesterol; RCT: reverse cholesterol transport; LDL: low density lipoprotein; HDL: high density lipoprotein; apoA1: apolipoprotein A-I; IFN-γ: interferon-γ; GAS: interferon-γ activation sequence; JAK: janus kinase; STAT: signal transducer and activator of transcription; EPA: eicosapentaenoic acid; UC: unesterified cholesterol; LPL: lipoprotein lipase; cAMP: cyclic AMP; PKA: protein kinase A; siRNA: short-interfering RNA; SR-A: scavenger receptors A; NPC1: Niemann-Pick type C; ZNF202: zinc finger protein 202.

References

1. Kreger BE, Odell PM, D’Agostino RD, Wilson P. Long-term individual cholesterol variability: natural course and adverse impact on morbidity and mortality: the Framingham Study. Am Heart J 1994; 127: 1607–14.

2. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham Study. J Am Med Assoc 1987; 257: 2176–80.

3. Ohashi R, Mu H, Wang X, Yao Q, Chen C. Reverse cholesterol transport and cholesterol efflux in atherosclerosis. J Clin Immunol 2005; 98: 845–56.

4. Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 2004; 101: 9774–9.

5. Wang N, Silver DL, Costet P, Tall AR. Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J Biol Chem 2000; 275: 33053–8.

6. Tsutsumi K, Inoue Y, Shima A, Iwasaki K, Kawamura M, Murase T. The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. J Clin Invest 1999; 92: 411–7.

7. Kusunoki M, Haru T, Tsutsumi K, Nakamura T, Miyata T, Sakakibara F, et al. The lipoprotein lipase activator, NO-1886, suppresses fat accumulation and insulin resistance in rats fed a high-fat diet. Diabetologia 2000; 43: 875–80.

8. Zhang C, Yin W, Liao D, Huang L, Tang C, Tsutsumi K, et al. NO-1886 upregulates ATP binding cassette transporter A1 and inhibits diet-induced atherosclerosis in Chinese Bama minipigs. J Lipid Res 2006; 47: 2055–63.

9. Dai XY, Ou X, Hao XR, Cao DL, Tang YL, Hu YW, et al. The effect of T9091317 on ATP-binding cassette transporter A1 and Niemann-Pick type C1 in apoE/- mice. J Cardiovasc Pharmacol 2008; 51: 467–75.

10. Hao XR, Cao DL, Hu YW, Li XX, Liu XH, Xiao J, et al. IFN-gamma down-regulates ABCA1 expression by inhibiting LXRs in a JAK/STAT signaling pathway-dependent manner. Atherosclerosis 2009; 203: 417–28.

11. Hu YW, Ma X, Li XX, Liu XH, Xiao J, Mo ZC, et al. Eicosapentaenoic acid reduces ABCA1 serine phosphorylation and impairs ABCA1-dependent cholesterol efflux through cyclic AMP/protein kinase A signaling pathway in THP-1 macrophage-derived foam cells. Atherosclerosis 2009; 204: e35–43.

12. Ma Y, Xu L, Rodriguez-Agudo D, Li X, Heuman DM, Hylemon PB, et al. 25-Hydroxycholesterol-3-sulfate regulates macrophage lipid metabolism via the LXR/SREBP-1 signaling pathway. Am J Physiol Endocrinol Metab 2008; 295: E1369–79.

13. Tang CK, Wang Z, Yi GH, Wang Z, Liu LS, Wan ZY, et al. Effect of rolipram on ATP binding cassette transporter 1 and cholesterol efflux in THP-1 macrophage-derived foam cell. Chin Pharmacol Bull 2003; 19: 1177–82.

14. Adorni MP, Zimetti F, Billheimer JT, Wang N, Rader DJ, Phillips MC, et al. The roles of different pathways in the release of cholesterol from macrophages. J Lipid Res 2007; 48: 2453–62.

15. Wang X, Collins HL, Ranalletta M, Fuku IV, Billheimer JT, Rothblat GH, et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest 2007; 117: 2216–24.

16. Venkateswaran A, Repa JJ, Lobaccaro JM, Bronson A, Mangelsdorf DJ, Edwards PA. Human white/murine ABCB8 mRNA levels are highly induced in lipid-loaded macrophages. A transcriptional role for specific oxysterols. J Biol Chem 2000; 275: 14700–7.

17. Costet PY, Luo N, Wang N, Tall AR. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/rexinoid X receptor. J Biol Chem 2000; 275: 28240–5.

18. Vermani R, Kolodgie FD, Burke AP, Farb A, Schwartz AM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20: 1262–75.

19. Eek MV, Pennings M, Hoekstra M, Oult R, Van Berkel TJ. scavenger receptor BI and ATP-binding cassette transporter A1 in reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol 2005; 16: 307–15.

20. Fielding CJ, Fielding PE. Intracellular cholesterol transport. J Lipid Res 1997; 38: 1503–21.

21. Rust S, Rosier M, Funke H, Reali J, Amourea Z, Piette J, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter1. Nat Genet 1999; 22: 352–5.

22. Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest 1999; 104: R25–31.

23. Klucen J, Buchler C, Orso E, Kaminski WE, Porsch-Ozcurumez M, Liebisch G, et al. ABCG1 (ABC8), the human homolog of the Droso- philia white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc Natl Acad Sci USA 2000; 97: 817–22.

24. Kennedy MA, Barrera GC, Nakamura K, Baldan A, Tarr P, Fishbein MC, et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab 2005; 1: 121–31.

25. Ma X, Hu YW, Mo ZG, Li XX, Liu XH, Xiao J, et al. NO-1886 up-regulates Niemann-Pick C1 Protein (NPC1) expression through liver X receptor alpha signaling pathway in vivo. Cardiovasc Drugs 2009; 23: 199–206.

26. Porsch-Ozcurumez M, Langmann T, Heimerl S, Borsukova H, Kaminski WE, drobnik W, et al. The zinc finger protein 202 (ZNF202) is a transcriptional repressor of ATP binding cassette transporter A1 (ABCA1) and ABCG1 gene expression and a modulator of cellular lipid efflux. J Biol Chem 2001; 276: 12427–33.

www.chinaphar.com
Chen SG et al

Acta Pharmacologica Sinica

1349